CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.
Takahashi
Harumi
H
Department of Pharmacotherapy, Meiji Pharmaceutical University, Tokyo, Japan. harumit@my-pharm.ac.jp
Wilkinson
Grant R
GR
Padrini
Roberto
R
Echizen
Hirotoshi
H
D000074:Acenocoumarol / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D006801:Humans; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D014859:Warfarin / Q000008:administration & dosage / Q000493:pharmacokinetics*
D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D000074:Acenocoumarol